Serina Therapeutics Inc (SER)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$2.73+1.49%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SER
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete enrollment and dosing in Cohort 1, progress to safety review and dose escalation, and target top-line data from single-ascending-dose arm in first half of 2027.
Stated as a priority in 2 of last 2 quarters. Management completed enrollment and dosing of all eight patients in Cohort 1 by July 2026, ahead of prior guidance to finish by end of Q3 2026. Top-line data from the single-ascending-dose arm is targeted for first half of 2027. The trajectory shows delivering progress consistent with management's stated timeline.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Completed enrollment and dosing in Cohort 1 ahead of prior guidance; top-line data targeted for first half of 2027.”
“Phase 1b registrational study underway; targeting completion of Cohort 1 enrollment by end of Q3 2026 and data in first half 2027.”
Close private placement financing to support advancement of SER-252 and improve liquidity position.
Stated as a priority in 2 of last 2 quarters. Management closed a $21.2 million private placement in March-April 2026, which contributed to cash and cash equivalents increasing from $3.1 million at end of 2025 to $23.0 million at June 30, 2026. The trajectory shows delivering on the financing objective and strengthening liquidity.
“Closing of March 2026 PIPE and related financing activities strengthened balance sheet.”
“Closed $21.2 million private placement financing to support advancement of SER-252.”
Advance proprietary POZ Platform technology to improve drug profiles and pursue partnerships including licensing agreements.
Stated as a priority in 2 of last 2 quarters. Management announced a development partnership with Gannet BioChem in June 2026 to support manufacturing activities for SER-252 and the broader pipeline, reflecting active steps to leverage the POZ platform. The trajectory shows delivering partnership progress consistent with stated strategy.
“Development partnership with Gannet BioChem to support process development and manufacturing for SER-252 and broader pipeline.”
“Building pipeline and partnership strategy to leverage POZ platform technology across multiple modalities.”
Control operating expenses and research and development costs while advancing clinical programs.
Stated as a priority in 2 of last 2 quarters. Operating expenses increased from $5.9 million in 2025-Q1 to $6.8 million in 2026-Q2, and R&D expenses rose from $3.0 million to $3.8 million over the same period, driven by higher headcount and clinical activity. Management continues disciplined expense management but expenses have grown modestly consistent with clinical progress.
“Operating expenses were $6.8 million, R&D expenses $3.8 million, increased due to higher headcount and clinical activity.”
“Operating expenses were $6.3 million, R&D expenses $3.2 million, reflecting disciplined spending.”
Strengthen Board of Directors with experienced members to support clinical and corporate objectives.
Newly stated in 2026-Q3 period with appointment of Farrell Simon to the Board in July 2026. This strategic hire adds commercial and business development expertise to support clinical and corporate goals. No prior quarters mention this priority.
Over the trailing year it converted 0.51x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
22 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.